The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Clinical

SWOG DMC says PEGPH20 unlikely to demonstrate OS improvement

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Halozyme Therapeutics Inc. announced it has been informed by SWOG, an independent network of researchers that design and conduct cancer clinical trials, that the SWOG phase Ib/II trial evaluating PEGPH20 plus modified FOLFIRINOX chemotherapy versus modified FOLFIRINOX alone in patients with previously untreated metastatic pancreas cancer has been temporarily closed to enrollment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe

YOU MAY BE INTERESTED IN

Clinical Roundup

Electric jolt technique offers possible avenue for early detection of pancreatic cancer, OHSU-led study finds

Scientists at Oregon Health & Science University have developed a technique using an electronic jolt and nanoparticles to reveal the telltale signal of an insidious form of cancer. The technique offers a new way to detect early signs of pancreatic cancer—a particularly deadly type of cancer because it isn’t detected until it’s progressed to later stages that are difficult to treat effectively. The new method would involve a simple blood draw among people who are considered higher risk due to family history or other factors.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account